Prospective Multi-Center Observational Study to Assess Effectiveness of Venclexta (Venetoclax) in Combination With Obinutuzumab in Population of Previously Untreated Chronic Lymphocytic Leukemia Patients in Routine Clinical Practice in Russian Federation (FIRST)
Latest Information Update: 01 Dec 2021
At a glance
- Drugs Obinutuzumab (Primary) ; Venetoclax (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Acronyms FIRST
- Sponsors AbbVie
Most Recent Events
- 18 Nov 2021 Status changed from recruiting to discontinued due to lack of recruitment.
- 18 Dec 2020 Status changed from not yet recruiting to recruiting.
- 12 Dec 2020 New trial record